CPRX: Catalyst Pharmaceuticals, Inc. Stock

by  •  • Comments Off on CPRX: Catalyst Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,732.99
Enterprise Value ($M) 1,595.36
Book Value ($M) 387.88
Book Value / Share 3.29
Price / Book 4.47
NCAV ($M) 137.10
NCAV / Share 1.16
Price / NCAV 12.64

Profitability (mra)
Return on Invested Capital (ROIC) 0.18
Return on Assets (ROA) 0.18
Return on Equity (ROE) 0.21

Liquidity (mrq)
Quick Ratio 2.68
Current Ratio 2.88

Balance Sheet (mrq) ($M)
Current Assets 219.33
Assets 470.11
Liabilities 82.23
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 398.20
Operating Income 86.81
Net Income 71.41
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 143.60
Cash from Investing -293.50
Cash from Financing -10.86

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 6.68 5.20
02-12 13G/A Flynn James E 8.34 51.06
01-25 13G/A State Street Corp 6.37 -13.79
01-22 13G/A BlackRock Inc. 14.80 0.84

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PUR
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION R
2023-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPOR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-25 101,709 658,152 15.45
2024-04-24 91,480 456,233 20.05
2024-04-23 121,719 405,990 29.98
2024-04-22 120,558 497,685 24.22

(click for more detail)

Similar Companies
COEP – Coeptis Therapeutics Holdings, Inc. CORT – Corcept Therapeutics Incorporated
COYA – Coya Therapeutics, Inc. CRBP – Corbus Pharmaceuticals Holdings, Inc.
CRDF – Cardiff Oncology, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Catalyst Pharmaceuticals